⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1661996 | 0.60 | — | — | |
| SCHEMBL29357583 | 0.60 | ADORA2A (0.36) | — | |
| SCHEMBL138622 | 0.60 | ADORA2A (0.36) | — | |
| SCHEMBL6022371 | 0.59 | — | — | |
| SCHEMBL5060846 | 0.58 | — | — | |
| SCHEMBL29504465 | 0.58 | — | — | |
| SCHEMBL253701 | 0.57 | — | — | |
| SCHEMBL326207 | 0.57 | — | — | |
| SCHEMBL374653 | 0.56 | — | — | |
| SCHEMBL1998363 | 0.56 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120107273-A1 | NEW PIPERAZINE COMPOUND AND USE THEREOF AS A HCV POLYMERASE INHIBITOR | JAPAN TOBACCO INC. (JP) | 2012-05-03 | — | — | US | claimed |
| US-8017612-B2 | therapeutic agent for hepatitis C; R)-4-(4-trifluoromethyl-benzenesulfonyl)-piperazine-1,3-dicarboxylic acid 3-(4-isopropyl-benzylamide) 1-pyridin-4-ylamide; enzyme inhibitors | JAPAN TOBACCO INC. (JP) | 2011-09-13 | — | — | US | claimed |
| EP-2009004-A1 | NOVEL PIPERAZINE COMPOUND, AND USE THEREOF AS HCV POLYMERASE INHIBITOR | Japan Tobacco, Inc. (JP) | 2008-12-31 | — | — | EP | claimed |
| US-20080081818-A1 | therapeutic agent for hepatitis C; R)-4-(4-trifluoromethyl-benzenesulfonyl)-piperazine-1,3-dicarboxylic acid 3-(4-isopropyl-benzylamide) 1-pyridin-4-ylamide; enzyme inhibitors | JAPAN TOBACCO INC. (JP) | 2008-04-03 | — | — | US | claimed |
| WO-2024074559-A1 | COMBINATION OF SUBSTITUTED 2,4 DIAMINO-QUINOLINE COMPOUNDS AND MEK INHIBITORS FOR USE IN THE TREATMENT OF LIVER CANCERS | GENOSCIENCE PHARMA (FR) | 2024-04-11 | — | — | WO | disclosed |
| EP-4349336-A1 | COMBINATION OF SUBSTITUTED 2,4 DIAMINO-QUINOLINE COMPOUNDS AND MEK INHIBITORS FOR USE IN THE TREATMENT OF LIVER CANCERS | Genoscience Pharma (FR) | 2024-04-10 | — | — | EP | disclosed |
| US-20230234942-A1 | COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | PTC THERAPEUTICS INC (US) | 2023-07-27 | — | — | US | disclosed |
| EP-4132923-A1 | COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | PTC Therapeutics, Inc. (US) | 2023-02-15 | — | — | EP | disclosed |
| US-11566025-B2 | Viral replication inhibitors | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2023-01-31 | — | — | US | disclosed |
| US-11261189-B2 | Substituted 2,4 diamino-quinoline as new medicament for fibrosis, autophagy and cathepsins B (CTSB), L (CTSL) and D (CTSD) related diseases | GENOSCIENCE PHARMA (FR) | 2022-03-01 | — | — | US | disclosed |
| EP-3846814-A1 | SUBSTITUTED 2,4 DIAMINO-QUINOLINE AS NEW MEDICAMENT FOR FIBROSIS, AUTOPHAGY AND CATHEPSINS B (CTSB), L (CTSL) AND D (CTSD) RELATED DISEASES | Genoscience Pharma (FR) | 2021-07-14 | — | — | EP | disclosed |
| EP-2978753-B1 | NOVEL VIRAL REPLICATION INHIBITORS | UNIV LEUVEN KATH (BE) | 2020-08-12 | — | — | EP | disclosed |
| US-6933283-B2 | 11-deoxy azalide antibacterials | ABBOTT LABORATORIES (US) | 2005-08-23 | — | — | US | disclosed |
| US-20040029818-A1 | Tricyclic macrolide antibacterial compounds | ABBVIE INC. | 2004-02-12 | — | — | US | disclosed |
| US-20040014687-A1 | Macrolide antibacterial compounds | ABBOTT LABORATORIES | 2004-01-22 | — | — | US | disclosed |
| US-20040014688-A1 | Oxolide antibacterials | ABBVIE INC. | 2004-01-22 | — | — | US | disclosed |
| US-20040014691-A1 | 9-Oxime macrolide antibacterials | ABBOTT LABORATORIES | 2004-01-22 | — | — | US | disclosed |
| US-20040014953-A1 | 11-Deoxy azalide antibacterials | ABBVIE INC. | 2004-01-22 | — | — | US | disclosed |
| US-20040009932-A1 | Antibacterial compounds with activity against penicillin-resistant streptococcus pneumoniae | ABBOTT LABORATORIES | 2004-01-15 | — | — | US | disclosed |
| US-6667306-B1 | Aminobenzothiazole and aminobenzoxazole derivatives; thrombosis | MILLENNIUM PHARMACEUTICALS, INC. | 2003-12-23 | — | — | US | disclosed |